Introduction
Kaplan-Meier (KM) survival curves are foundational to oncology clinical trials and can be central to how efficacy is assessed for cytotoxic chemotherapy, targeted therapies, immunotherapies, and cellular therapies. Endpoints such as overall survival (OS), progression-free survival (PFS), event-free survival (EFS), and duration of response (DoR) are almost universally presented